$110.1M
+$110.1M this year1 filing since 2026 · latest Equity filed
Climb Bio is a clinical-stage biotechnology company in Wellesley Hills, Massachusetts developing disease-modifying monoclonal antibodies for immune-mediated diseases. Its lead candidate, budoprutug, is an anti-CD19 antibody that depletes B cells and is being developed across B-cell-mediated conditions including primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus. A second program, CLYM116, is an anti-APRIL monoclonal antibody for IgA nephropathy. The company trades publicly as CLYM and was formerly known as Eliem Therapeutics, adopting the Climb Bio name in October 2024.
What sets it apart
Climb Bio concentrates on differentiated antibodies against validated immunology targets — CD19 B-cell depletion and APRIL — and pursues indications where patients have limited therapeutic options, particularly autoimmune kidney disease.
An investigational anti-CD19 monoclonal antibody that depletes B cells, in clinical development for B-cell-mediated autoimmune diseases including primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus.
